Chongqing Evaheart Secures Near $100M in Series A for Heart Failure Platform
Chongqing Evaheart Medical Device Co., Ltd has reportedly secured close to USD 100 million in...
Chronic disease
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in...
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...
Huadong Medicine Expands Global Partnership with Scohia Pharma for SCO-094
China-based Huadong Medicine Co., Ltd (SHE: 000963) and Japanese firm Scohia Pharma Inc. have announced...
Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has...
Shanghai Pharmaceuticals’ X842 Accepted for NMPA Review for Reflux Esophagitis
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...
Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...
NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis
The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...
ThinmedTech Partners with West China Hospital for CKD Digital Therapy
ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership...
Junshi Biosciences’ JS401 Accepted for Review by China’s NMPA for Hyperlipidemia
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration...
Dartsbio Pharmaceuticals Secures RMB 100 Million in Series B Financing
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a...
AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab
China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole...
Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study
China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...
Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval
Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...
China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan
The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for...
CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment
UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...
Luye Pharma’s Paliperidone Palmitate Accepted for NMPA Review
China-based Luye Pharma Group (HKG: 2186) has announced that the market filing for its paliperidone...
Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab
Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...